Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases
European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The CO...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Online |
| Hizkuntza: | ingelesa |
| Argitaratua: |
Frontiers Media SA
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | 22974 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1869513875618004992 |
|---|---|
| author | Giuseppe Di Giovanni Rona R. Ramsay |
| author_browse | Giuseppe Di Giovanni Rona R. Ramsay |
| author_facet | Giuseppe Di Giovanni Rona R. Ramsay |
| author_sort | Giuseppe Di Giovanni |
| collection | Directory of Open Access Books |
| description | European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” is a good example of the advances possible through interdisciplinary collaboration on difficult problems. COST Action CM1103 brought together 28 research groups from 18 countries to collaborate for four years on multi-target drug design for complex neuropathologies. The interdisciplinary expertise of the members is spans the range from computational enzymology to human studies, providing outstanding opportunities for the interdisciplinary development of trainees, and is reflected in the articles in this e-book. This Research Topic covers progress in multi-target drug design for the complex neuropathologies of the monoamine system that are apparent, for example, in Alzheimer’s disease. After a mini-review to introduce the topic of multi-target drug design, the other articles review the Research topic from their own perspective, two from computational approaches, three from medicinal chemistry, two from molecular pharmacology, and two from studies in whole brain. This multi-faceted approach describes new compounds, new methodology, and advances in the basic science of understanding the brain. This Ebook is based upon work from COST Action (CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain"), supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe’s research and innovation capacities. It allows researchers, engineers and scholars to jointly develop their own ideas and take new initiatives across all fields of science and technology, while promoting multi- and interdisciplinary approaches. COST aims at fostering a better integration of less research intensive countries to the knowledge hubs of the European Research Area. The COST Association, an International not-for-profit Association under Belgian Law, integrates all management, governing and administrative functions necessary for the operation of the framework. The COST Association has currently 36 Member Countries. www.cost.eu |
| format | Online |
| id | doab-20.500.12854ir-60157 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-601572024-04-05T12:35:18Z Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases Giuseppe Di Giovanni Rona R. Ramsay RC321-571 RM1-950 Q1-390 Rationale drug design GPCR agonists Molecular dynamic simulations Neurodegenerative Diseases monoamine pharmacology Oxidative Stress Multi-target designed ligands Epilepsy Chemi-informatics thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” is a good example of the advances possible through interdisciplinary collaboration on difficult problems. COST Action CM1103 brought together 28 research groups from 18 countries to collaborate for four years on multi-target drug design for complex neuropathologies. The interdisciplinary expertise of the members is spans the range from computational enzymology to human studies, providing outstanding opportunities for the interdisciplinary development of trainees, and is reflected in the articles in this e-book. This Research Topic covers progress in multi-target drug design for the complex neuropathologies of the monoamine system that are apparent, for example, in Alzheimer’s disease. After a mini-review to introduce the topic of multi-target drug design, the other articles review the Research topic from their own perspective, two from computational approaches, three from medicinal chemistry, two from molecular pharmacology, and two from studies in whole brain. This multi-faceted approach describes new compounds, new methodology, and advances in the basic science of understanding the brain. This Ebook is based upon work from COST Action (CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain"), supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe’s research and innovation capacities. It allows researchers, engineers and scholars to jointly develop their own ideas and take new initiatives across all fields of science and technology, while promoting multi- and interdisciplinary approaches. COST aims at fostering a better integration of less research intensive countries to the knowledge hubs of the European Research Area. The COST Association, an International not-for-profit Association under Belgian Law, integrates all management, governing and administrative functions necessary for the operation of the framework. The COST Association has currently 36 Member Countries. www.cost.eu 2021-02-12T04:45:04Z 2021-02-12T04:45:04Z 2017-07-06 13:27:36 2017 book 22974 16648714 9782889451234 https://directory.doabooks.org/handle/20.500.12854/60157 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Structure-Based_Drug_Design_for_Diagnosis_and_Treatment_of_Neurological_Diseases/1154#nogo http://journal.frontiersin.org/researchtopic/4246/structure-based-drug-design-for-diagnosis-and-treatment-of-neurological-diseases Frontiers Media SA 10.3389/978-2-88945-123-4 10.3389/978-2-88945-123-4 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889451234 204 open access |
| spellingShingle | RC321-571 RM1-950 Q1-390 Rationale drug design GPCR agonists Molecular dynamic simulations Neurodegenerative Diseases monoamine pharmacology Oxidative Stress Multi-target designed ligands Epilepsy Chemi-informatics thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences Giuseppe Di Giovanni Rona R. Ramsay Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases |
| title | Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases |
| title_full | Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases |
| title_fullStr | Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases |
| title_full_unstemmed | Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases |
| title_short | Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases |
| title_sort | structure based drug design for diagnosis and treatment of neurological diseases |
| topic | RC321-571 RM1-950 Q1-390 Rationale drug design GPCR agonists Molecular dynamic simulations Neurodegenerative Diseases monoamine pharmacology Oxidative Stress Multi-target designed ligands Epilepsy Chemi-informatics thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| topic_facet | RC321-571 RM1-950 Q1-390 Rationale drug design GPCR agonists Molecular dynamic simulations Neurodegenerative Diseases monoamine pharmacology Oxidative Stress Multi-target designed ligands Epilepsy Chemi-informatics thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| url | 22974 |
| work_keys_str_mv | AT giuseppedigiovanni structurebaseddrugdesignfordiagnosisandtreatmentofneurologicaldiseases AT ronarramsay structurebaseddrugdesignfordiagnosisandtreatmentofneurologicaldiseases |